Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Filter
Select filter(s)
Ciclosporin
Verkazia
Routinely available
SMC (SMC2111)
12/11/2025

Indication

Treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents (until the age of 18)

Treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents (until the age of 18)

Therapeutic Area

Eye

Status Description

Routinely available in line with national guidance

Formulation

1mg/mL (0.1%) eye drops emulsion

Comments

Link to Advice

SMC2111

Advice Published

10/12/2018

SMC Submission Type

Full

SMC Status

Accepted